A single scale for comparing dose-intensity of all chemotherapy regimens in breast cancer: Summation dose-intensity

Journal of Clinical Oncology

Volumn 16, Issue 9, 1998, Pages 3137-3147

  Hryniuk, W ^a   Frei III, E ^b   Wright, F A ^b  

^a KARMANOS CANCER INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; MELPHALAN; METHOTREXATE; MITOXANTRONE; NAVELBINE; PACLITAXEL; VINCRISTINE;

ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; DRUG RESPONSE; FEMALE; HUMAN; METASTASIS; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0031720392     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.9.3137     Document Type: Article

References (105)

1. Hryniuk W, Bush H: The importance of dose-intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 2:1281-1288, 1984
2. Hryniuk W, Levine MN: Analysis of dose-intensity for adjuvant chemotherapy trials in stage II breast cancer. J Clin Oncol 4:1162-1170, 1986
3. Bastholt L, Dalmark M, Gjedde SB, et al: Dose-response relationship of epirubicin in the treatment of postmenopausal patients with metastatic breast cancer: A randomized study of epirubicin at four different dose levels performed by the Danish Breast Cancer Cooperative Group. J Clin Oncol 14:1146-1155, 1996
4. Bastit P, Chevallier B, Roche H, et al with the French Epirubicin Study Group (FESG): Epirubicin dose and schedule dependency in 3 FEC regimens (reg) first line in metastatic breast cancer early report. Proc Am Soc Clin Oncol 13:67, 1994 (abstr)
5. Becher R, Wandle U, Kloke O, et al: Randomized study of different doses of epirubicin and identical doses of cyclophosphamide in advanced breast cancer. Proc Am Soc Clin Oncol 9:46, 1990 (abstr)
6. Beretta G, Tabiadon D, Tedeschi L, et al: Front-line treatment with CMF variations for advanced breast carcinoma: A randomized study. Proc Am Soc Clin Oncol 5:77, 1986 (abstr)
7. Bezwoda WR, Seymour L, Dansey RD: High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: A randomized trial. J Clin Oncol 13:2483-2489, 1995
8. Carmo-Pereira J, Costa FO, Henriques E, et al: A randomized trial of two regimens of cyclophosphamide, methotrexate, 5-fluorouracil, and prednisone in advanced breast cancer. Cancer Chemother Pharmacol 17:87-90, 1986
9. Carmo-Pereira J, Costa FO, Henriques E, et al: A comparison of two doses of Adriamycin in the primary chemotherapy of disseminated breast carcinoma. Br J Cancer 56:471-473, 1987
10. Engelsman E, Klijn JCM, Rubens RD, et al: "Classical" CMF versus a 3-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer. Eur J Cancer 27:966-970, 1991
11. Focan C, Andrien JM, Closon MT, et al: Dose-response relationship of epirubicin-based first-line chemotherapy for advanced breast cancer: A prospective randomized trial. J Clin Oncol 11:1253-1263, 1993
12. French Epirubicin Study Group. A prospective randomized trial comparing epirubicin monochemotherapy to two fluorouracil, cyclophosphamide, and epirubicin regimens differing in epirubicin dose in advanced breast cancer patients. J Clin Oncol 9:305-312, 1991
13. Habeshaw T, Paul J, Jones R, et al: Epirubicin at two dose levels with prednisolone as treatment for advanced breast cancer: The results of a randomized trial. J Clin Oncol 9:295-304, 1991
14. Hortobagyi GN, Bodey GP, Buzdar AU, et al: Evaluation of high-dose versus standard FAC chemotherapy for advanced breast cancer in protected environment units: A prospective randomized study. J Clin Oncol 5:354-364, 1987
15. Horton J, Olson KB, Sullivan J, et al: 5-Fluorouracil in cancer: An improved regimen. Ann Int Med 73:897-900, 1970
16. Marschner N, Kreienberg R, Souchon R, et al: Evaluation of the importance and relevance of dose-intensity using epirubicin and cyclophosphamide in metastatic breast cancer: Interim analysis of a prospective randomized trial. Semin Oncol 21:10-16, 1994 (suppl 1)
17. Nabholtz JM, Gelmon K, Bontenbal M, et al: Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol 14:1858-1867, 1996
18. Sears ME, Tucker W, Coltman CA, et al: Effectiveness of various dosage schedules of methotrexate in advanced breast carcinoma. Cancer Chemother Rep 53:93, 1969 (abstr)
19. Tannock IF, Boyd NF, DeBoer G, et al: A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorourocil chemotherapy for patients with metastatic breast cancer. J Clin Oncol 6:1377-1387, 1988
20. Ardizzoni A, Venturini M, Sertoli MR, et al: Granulocyte-macrophage colony-stimulating factor (GM-CSF) allows acceleration and dose-intensity increase of CEF chemotherapy: A randomised study in patients with advanced breast cancer. Br J Cancer 69:385-391, 1994
21. 2) in the FEC regimen significantly increases response rates. An international randomised phase III study in metastatic breast cancer. Ann Oncol 8:155-162, 1997
22. Bonneterre J, Roche H, Bremond A, et al: A randomized trial of adjuvant chemotherapy with FEC 50 vs FEC 100 for node-positive operable breast cancer: Early report. Proc Am Soc Clin Oncol 11:66, 1992 (abstr)
23. Bremond A, Kerbrat P, Fumoleau P, et al: Five-year follow-up results of a randomized trial testing the role of the dose-intensity and duration of chemotherapy in node-positive premenopausal breast cancer patients. Proc Am Soc Clin Oncol 15:113, 1996 (abstr)
24. Carter SK: Single and combination nonhormonal chemotherapy in breast cancer. Cancer 30:1543-1555, 1972
25. Dimitrov N, Anderson S, Fisher B, et al: Dose-intensification and increased total dose of adjuvant chemotherapy for breast cancer (BC): Findings from NSABP B-22. Proc Am Soc Clin Oncol 13:63, 1994 (abstr)
26. Fetting J, Gray R, Abeloff M, et al: CAF vs a 16-week multidrug regimen as adjuvant therapy for receptor-negative, node-positive breast cancer: An intergroup study. Proc Am Soc Clin Oncol 14:96, 1995 (abstr)
27. Wood WC, Budman DR, Korzun AH, et al: Dose and dose-intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. New Engl J Med 330:1253-1259, 1994
28. Rodenhius S, Richel DJ, Baars JW, et al: A randomized single-institution study of high-dose chemotherapy with cyclophosphamide, thiotepa and carboplatin in high-risk breast cancer. Proc Am Assoc Cancer Res 38:438, 1997 (abstr)
29. Siu L, Tannock IF: Chemotherapy dose escalation: Case unproven. J Clin Oncol 15:2765-2768, 1997
30. Frei E, Elias A, Hryniuk W: The relationship between high-dose treatment and combination chemotherapy: The concept of summation dose intensity. Clin Cancer Res 1998 (in press)
31. Hosmer DW, Lemeshow S: Applied Logistic Regression. New York, NY, Wiley, 1989, p 307
32. Kendall MG, Stuart A: The Advanced Theory of Statistics, vol. 2 (ed 3). New York, NY, Wiley, 1978
33. Torri V, Korn L, Simon R: Dose-intensity analysis in advanced ovarian cancer patients. Br J Cancer 67:190-197, 1993
34. McCullagh P: Generalized Linear Models (ed 2). London, England, Chapman & Hall, 1989
35. Bates DM, Watts DG: Nonlinear Regression Analysis and its Applications. New York, NY, Wiley, 1988
36. Ott RL: An Introduction to Statistical Methods and Data Analysis (ed 4). Pacific Grove, CA, Duxbury Press, 1993
37. Hryniuk W, Schilsky RL (eds): Principles of antineoplastic drug development and pharmacology, New York, NY, Dekker, 1996, pp 263-279
38. Carbone PP, Bauer M, Band P, et al: Chemotherapy of disseminated breast cancer: Current status and prospects. Cancer 39: 2916-2933, 1977
39. Creech RH, Catalano RB, Harris DT, et al: Low versus high-dose Adriamycin therapy of metastatic breast cancer. Proc Am Soc Clin Oncol C-36:315, 1978 (abstr)
40. Hoogstraten B, George SL, Samal B, et al: Combination chemotherapy and Adriamycin in patients with advanced breast cancer: A Southwest Oncology Group study. Cancer 38:13-20, 1976
41. De Lena M, Brambilla C, Morabito A, et al: Adriamycin plus vincristine compared to and combined with cyclophosphamide, methotrexate and 5-fluorouracil for advanced breast cancer. Cancer 35: 1108-1115, 1975
42. Perez DJ, Harvey VJ, Robinson BA, et al: A randomized comparison of single-agent doxorubicin and epirubicin as first-line cytotoxic therapy in advanced breast cancer. J Clin Oncol 9:2148-2152, 1991
43. Ahmann DL, Bisel HF, Eagan RT, et al: Controlled evaluation of NSC-123127 in patients with disseminated breast cancer. Cancer Chemother Rep 58:877-882, 1974
44. Steiner R, Stewart JF, Cantwell BMJ, et al: Adriamycin alone or combined with vincristine in the treatment of advanced breast cancer. Eur J Cancer Clin Oncol 19:1553-1557, 1983
45. Tormey DC, Gleman R, Band PR, et al: Comparison of induction chemotherapies for metastatic breast cancer. Cancer 50:1235-1244, 1982
46. Rubens RD, Begent RHJ, Knight RK, et al: Combined cytotoxic and progestogen therapy for advanced breast cancer. Cancer 42: 1680-1686, 1978
47. Gunderson S, Kvinnsland S, Klepp O, et al: Weekly Adriamycin versus VAC in advanced breast cancer: A randomized trial. Eur J Cancer Clin Oncol 22:1431-1434, 1986
48. Gunderson S, Kvinnsland S, Klepp O, et al: Weekly Adriamycin vs 4-epidoxorubicin every second week in advanced breast cancer: A randomized trial. Eur J Cancer 26:45-48, 1990.
49. Twelves CJ, Ramirez AJ, Richards MA, et al: A comparison of response, survival and quality of life (QOL) using 2 doxorubicin (Dox) schedules of equal dose-intensity in metastatic breast cancer. Br J Cancer 62:498-499, 1990
50. Lawton PA, Ostrowski MJ, Young T, et al: Efficacy and toxicity of single-agent chemotherapy in advanced breast carcinoma. Br J Cancer 61:177, 1990 (abstr)
51. Martin M, Diaz-Rubio E, Casado A, et al: Carboplatin: An active drug in metastatic breast cancer. J Clin Oncol 10:433-437, 1992
52. Kolaric K, Vukas D: Carboplatin activity in untreated metastatic breast cancer patients - Result of a phase II study. Cancer Chemother Pharmacol 27:409-412, 1991
53. O'Brien MER, Talbot DC, Smith IE: Carboplatin in the treatment of advanced breast cancer: A phase II study using pharmacokinetically guided dose schedule. J Clin Oncol 11:2112-2117, 1993
54. Kolaric K, Roth A: Phase II clinical trial of cis-dichlorodiammineplatinum (Cis DDP) for antitumorigenic activity in previously untreated patients with metastatic breast cancer. Cancer Chemother Pharmacol 11:108-112, 1983
55. Sledge GW, Loehrer PJ, Roth BJ, et al: Cisplatin as first-line therapy for metastatic breast cancer. Proc Am Soc Clin Oncol 6:206, 1987 (abstr)
56. Talley RW, Vaitkevicius VK, Leighton GA: Comparison of cyclophosphamide and 5-fluorouracil in the treatment of patients with metastatic breast cancer. Clin Pharmacol Ther 6:740-748, 1965
57. Nemoto T, Dao TL: 5-Fluorouracil and cyclophosphamide in disseminated breast cancer. NY State J Med 71:554-558, 1971
58. Firat D, Olshin S: Treatment of metastatic carcinoma of the female breast with combination of hormones and other chemotherapy. Cancer Chemother Rep 52:743-750, 1968
59. Rubens RD, Knight RK, Hayward JL: Chemotherapy of advanced breast cancer: A controlled randomized trial of cyclophosphamide versus a four-drug combination. Br J Cancer 32:730-736, 1975
60. Gold GL, Salvin LG, Shnider BI: A comparative study with three alkylating agents: Mechlorethamine, cyclophosphamide, and uracil mustard. Cancer Chemother Rep 16:417-419, 1962
61. Sledge GW, Roth BJ, Munshi N, et al: High-dose epirubicin (EPI) as initial therapy for advanced breast cancer. Proc Am Soc Clin Oncol 11:85, 1992 (abstr)
62. Venturini M, Michelotti A, Del Mastro L, et al: Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer. J Clin Oncol 14:3112-3120, 1996
63. Nielsen D, Dombernowsky P, Skovsgaard T, et al: Epirubicin or epirubicin and vindesine in advanced breast cancer: A phase III study. Ann Oncol 1:275-280, 1990
64. Dogliotti L, Berruti A, Buniva T, et al: Lonidamine significantly increases the activity of epirubicin in patients with advanced breast cancer: Results from a multicenter prospective randomized trial. J Clin Oncol 14:1165-1172, 1996
65. Wander HE, Rauschning W, Meyer D, et al: Phase II study with etoposide in previously untreated breast cancer. Cancer Chemother Pharmacol 24:261-263, 1989
66. Lemkin R, Dollinger MR: Combination vs single-drug therapy in advanced breast cancer. Proc Am Assoc Cancer Res 14:37, 1973 (abstr)
67. Smalley RV, Murphy S, Huguley CM, et al: Combination versus sequential five-drug chemotherapy in metastatic carcinoma of the breast. Cancer Res 36:3911-3916, 1976
68. Chlebowksi RT, Irwin LE, Pugh RP, et al: Survival of patients with metastatic breast cancer treated with either combination or sequential chemotherapy. Cancer Res 39:4503-4506, 1979
69. Baker LH, Vaughn CB, Al-Sarraf M, et al: Evaluation of combination vs sequential cytotoxic chemotherapy in the treatment of advanced breast cancer. Cancer 53:513-518, 1974
70. Ansfield F, Klotz J, Nealon T, et al: A phase III study comparing the clinical utility of four regimens of 5-fluorouracil: A preliminary report. Cancer 39:34-40, 1977
71. Eastern Cooperative Group in Solid Tumor Chemotherapy: Comparison of antimetabolites in the treatment of breast and colon cancer. J Am Med Assoc 200:770-778, 1967
72. Canellos GP, Pocock SJ Taylor SG, et al: Combination chemotherapy for metastatic breast carcinoma - Prospective comparison of multiple drug therapy with L-phenylalanine mustard. Cancer 38:1882-1886, 1976
73. Sears ME, Haut A, Eckles N: Melphalan (NSC-8806) in advanced breast cancer. Cancer Chemother Rep 50:271-279, 1996
74. Nevinny HB, Hall TC, Haines C, et al: Comparison of methotrexate (NSC-740) and testosterone propionate (NSC-9166) in the treatment of breast cancer. J Clin Pharmacol 8:126-129, 1968
75. Vogler WR, Furtado VP, Huguley CM: Methotrexate for advanced breast cancer of the breast. Cancer 21:26-30, 1968
76. Greening WP: Methotrexate in the treatment of advanced cancer of the breast, in Porter, Wiltshaw (eds): Symposium on Methotrexate in the Treatment of Cancer. Baltimore, MD, Williams & Wilkins, 1962, pp 29-33
77. Wright JC, Cobb JP, Golomb FM, et al: Chemotherapy of disseminated carcinoma of the breast. Ann Surg 150:221-240, 1959
78. Harris AL, Cantwell BMJ, Carmichael J, et al: Comparison of short-term and continuous chemotherapy (mitoxantrone) for advanced breast cancer. Lancet 335:186-190, 1990
79. Landys K, Borgstrom S, Andersson T, et al: Mitoxantrone as first-line treatment in advanced breast cancer: A phase II study. Recent Advances in Chemotherapy: A Focus on Novantrone, p-11
80. Smyth JF, Cornbleet MA, Stuart-Harris RC, et al: Mitoxantrone as first-line chemotherapy for advanced breast cancer: Results of a European collaborative study. Semin Oncol 11:15-18, 1984
81. Fumoleau P, Delgado FM, Delozier T, et al: Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol 11:1245-1252, 1993
82. Garcia-Conde J, Lluch A, Martin M, et al: Phase II trial of weekly IV vinorelbine in first-line advanced breast cancer chemotherapy. Ann Oncol 5:854-857, 1994
83. Weber B, Vogel C, Jones S, et al: A US multicenter phase II trial of navelbine in advanced breast cancer. Proc Am Soc Clin Oncol 12:61, 1993 (abstr)
84. Romero A, Rabinovich M, Vallejo C, et al: Promising preliminary results of weekly navelbine as first-line chemotherapy for metastatic breast cancer. Proc Am Soc Clin Oncol 12:76, 1993 (abstr)
85. Bruno S, Puerto VL, Mickiewicz E, et al: Phase II trial of weekly IV vinorelbine as a single agent in first-line advanced breast cancer chemotherapy. The Latin-American experience. Am J Clin Oncol 18:5,392-396, 1995
86. 2 by 3-hour infusion without G-CSF as a first-line therapy in patients with metastatic breast cancer. Proc Am Soc Clin Oncol 179:128, 1996 (abstr)
87. Gelmon KA, O'Reilly S, Plenderleith IH, et al: Biweekly paclitaxel and cisplatin in the treatment of metastatic breast cancer. Proc Am Soc Clin Oncol 13:71, 1994 (abstr)
88. Bishop JF, Dewar J, Tattersall MH, et al: A randomized phase III study of Taxol (paclitaxel) vs CMFP in untreated patients with metastatic breast cancer. Proc Am Soc Clin Oncol 16:153a, 1997 (abstr)
89. Davidson NG, Chick J, Campbell N: Single-agent paclitaxel in patients at first relapse following adjuvant chemotherapy for breast cancer. Taxol in the management of breast cancer: Current perspectives and new data. Semin Oncol 22:2-6, 1995
90. Mamounas E, Brown A, Fisher B, et al: 3-Hour high-dose Taxol infusion in advanced breast cancer: An NSABP phase II study. Proc Am Soc Clin Oncol 14:127, 1995 (abstr)
91. Trudeau ME, Eisenhauer E, Lofters W, et al: Phase II study of taxotere as first-line chemotherapy for metastatic breast cancer. Proc Am Soc Clin Oncol 12:64, 1993 (abstr)
92. Fumoleau P, Chevallier B, Dieras V, et al: Evaluation of two doses of Taxotere (docetaxel) as first line in advanced breast cancer. Breast Cancer Res Treat 32:34, 1994
93. Hudis CA, Seidman AD, Crown JPA, et al: Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer. J Clin Oncol 14:58-65, 1996
94. 2 as first-line chemotherapy for patients with advanced breast cancer: Report of the clinical screening group of the EORTC. Br J Cancer 74:650-656, 1996
95. Hortobagyi GN, Hryniuk WH, Frye D, et al: Dose-intensity (DI) analysis of high-dose (HD) chemotherapy for metastatic breast cancer (MBC). Proc Am Assoc Cancer Res 1537, 1989 (abstr)
96. Savarese DMF, Hsieh C, Stewart FM: Clinical impact of chemotherapy dose escalation in patients with hematologic malignancies and solid tumors. J Clin Oncol 15:2981-2995, 1997
97. Levin L, Hryniuk WM: Dose-intensity analysis of chemotherapy regimens in ovarian carcinoma. J Clin Oncol 5:756-757, 1987
98. DeVita VT, Hubbard SM, Young RC, et al: The role of chemotherapy in diffuse aggressive lymphomas. Semin Hematol 25: 2-10, 1988
99. Muss HB, Thor AD, Berry DA, et al: c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. New Engl J Med 330:1260-1266, 1994
100. Blomquist C, Elomaa I, Rissanen P, et al: Influence of treatment schedule on toxicity and efficacy of cyclophosphamide, epirubicin, and fluorouracil in metastatic breast cancer: A randomized trial comparing weekly and every-4-week administration. J Clin Oncol 11:467-473, 1993
101. Wright JC, Cobb JP, Golomb FM, et al: Chemotherapy of disseminated carcinoma of the breast. Ann Surg 150:221-240, 1959
102. Zubrod CG, Schneiderman M, Frei E III, et al: Appraisal of methods for the study of chemotherapy on cancer in man: Comparative therapeutic trial of nitrogen mustard and triethylene throphosphoramide. J Chronic Dis 11:7-32, 1960
103. Peters WP, Jones RB, Vredenburgh J, et al: A large, prospective, randomized trial of high-dose combination alkylating agents with autologous cellular support as consolidation for patients with metastatic breast cancer achieving complete remission after intensive doxorubicin-based induction therapy. Proc Am Soc Clin Oncol 15:121, 1996 (abstr)
104. Canellos GP: Selection bias in trials of transplantation for metastatic breast cancer: Have we picked the apple before it is ripe? J Clin Oncol 15:3169-3170, 1997
105. DeVita VT: Cancer Principles and Practice of Oncology (ed 5). Philadelphia, PA, Lippincott-Raven, 1996, p 335